


A2
Sub B1
1. (Amended) A formulation suitable for parenteral or oral administration, said formulation comprising an ionizable substituted indolinone of Formula (I);



wherein

R^1 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, hydroxy, alkoxy, C-carboxy, O-carboxy, acetyl, C-amido, C-thioamido, sulfonyl and trihalomethanesulfonyl;

R^2 is selected from the group consisting of hydrogen, halo, alkyl, cycloalkyl, aryl, heteroaryl and heteroalicyclic;

R^3 , R^4 , R^5 and R^6 are independently selected from the group consisting of hydrogen, alkyl, trihaloalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, mercapto, alkylthio, arylthio, sulfinyl, sulfonyl, S-sulfonamido, N-sulfonamido, trihalomethane-sulfonamido, carbonyl, C-carboxy, O-carboxy, C-amido, N-amido, cyano, nitro, halo, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, amino and $-NR^{11}R^{12}$;

R^{11} and R^{12} are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, carbonyl, acetyl, sulfonyl, trifluoromethanesulfonyl and, combined, a five- or six-member heteroalicyclic ring;

R^3 and R^4 , R^4 and R^5 , or R^5 and R^6 may combine to form a six-member aryl ring, a methylenedioxy group or an ethylenedioxy group;

Int 7
A 2
cont R⁷ is selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, carbonyl, acetyl, C-amido, C-thioamido, amidino, C-carboxy, O-carboxy, sulfonyl and trihalomethane-sulfonyl;

R⁹ is -(alk₁)Z, wherein Alk₁ is selected from the group consisting of alkyl, alkenyl or alkynyl, and Z is a polar group;

R⁸ and R⁹ are independently selected from hydrogen and unsubstituted lower alkyl, one or more polyoxyhydrocarbyl compounds and a pharmaceutically acceptable carrier therefor, wherein said ionizable substituted indolinone is solubilized by combining said indolinone with a molar equivalent of a base solution or an acid solution.

A 2 3. (Amended) The formulation of claim 1, wherein said ionizable substituted indolinone is 3-[2,4-dimethyl-5-(2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrol-3-yl]-propionic acid, or a pharmaceutically acceptable salt, prodrug, derivative, or analog thereof.

4. (Amended) The formulation of claim 1, wherein said formulation is suitable for parenteral administration.

A 3 7. (Amended) The formulation of claim 1, wherein each of said one or more polyoxyhydrocarbyl compounds is independently selected from the group consisting of water soluble carbohydrates, water soluble carbohydrate derivatives, water soluble polypeptides, water soluble polymers, water soluble mixed oxyalkylene polymers, the polymeric forms of ethylene glycol, and combinations thereof.

8. (Amended) The formulation of claim 1, wherein each of said one or more polyoxyhydrocarbyl compounds is independently selected from the group consisting of polyethylene glycol 300, polyethylene glycol 400, propyleneglycol, glycerin, and combinations thereof.

A 4 10. (Amended) The formulation of claim 1, wherein said base solution is selected from the group consisting of sodium hydroxide, ammonium hydroxide, triethylamine, ethylenediamine, N-methyl-D-glucamine, choline, and triethanolamine.

A4
C24 11. (Amended) The formulation of claim 1, wherein said acid solution is selected from the group consisting of hydrochloric acid, sulfuric acid, formic acid, lactic acid, malic acid, succinic acid, acetic acid, methane sulfonic acid, benzene sulfonic acid, and phosphoric acid.

A5 13. (Amended) The formulation of claim 1, wherein said pharmaceutically acceptable carrier further comprises one or more buffers.

A6 16. (Amended) The formulation of claim 1, wherein said pharmaceutically acceptable carrier further comprises one or more pharmaceutically acceptable surfactants.

A7 20. (Amended) The formulation of claim 1, wherein said pharmaceutically acceptable carrier further comprises one or more pharmaceutically acceptable preservatives.

A8 23. (Amended) The formulation of claim 1, wherein said pharmaceutically acceptable carrier further comprises one or more antioxidants.


A9 26. (Amended) The formulation of claim 1, wherein said pharmaceutically acceptable carrier further comprises one or more pharmaceutically acceptable alcohols.

A10 30. (Amended) The formulation of claim 1, wherein said pharmaceutically acceptable carrier further comprises one or more pharmaceutically acceptable oils.

A11 33. (Amended) The formulation of claim 1, wherein said formulation is suitable for oral administration.

A12 36. (Amended) The formulation of claim 33, wherein each of said one or more polyoxyhydrocarbyl compounds is independently selected from the group consisting of water soluble carbohydrates, water soluble carbohydrate derivatives, water soluble polypeptides, water soluble polymers, water soluble mixed oxyalkylene polymers, and the polymeric forms of ethylene glycol.

A13 76. (Amended) A method of making a formulation suitable for oral administration comprising admixing an ionizable substituted indolinone of Formula (I);



A13

wherein

R^1 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, hydroxy, alkoxy, C-carboxy, O-carboxy, acetyl, C-amido, C-thioamido, sulfonyl and trihalomethanesulfonyl;

R^2 is selected from the group consisting of hydrogen, halo, alkyl, cycloalkyl, aryl, heteroaryl and heteroalicyclic;

R^3 , R^4 , R^5 and R^6 are independently selected from the group consisting of hydrogen, alkyl, trihaloalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, mercapto, alkylthio, arylthio, sulfinyl, sulfonyl, S-sulfonamido, N-sulfonamido, trihalomethane-sulfonamido, carbonyl, C-carboxy, O-carboxy, C-amido, N-amido, cyano, nitro, halo, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, amino and $-NR^{11}R^{12}$;

R^{11} and R^{12} are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, carbonyl, acetyl, sulfonyl, trifluoromethanesulfonyl and, combined, a five- or six-member heteroalicyclic ring;

R^3 and R^4 , R^4 and R^5 , or R^5 and R^6 may combine to form a six-member aryl ring, a methylenedioxy group or an ethylenedioxy group;

R^7 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, carbonyl, acetyl, C-amido, C-thioamido, amidino, C-carboxy, O-carboxy, sulfonyl and trihalomethane-sulfonyl;

A13
cont


R^9 is $-(alk_1)Z$, wherein Alk_1 is selected from the group consisting of alkyl, alkenyl or alkynyl, and Z is a polar group;

R^8 and R^9 are independently selected from hydrogen and unsubstituted lower alkyl, one or more pharmaceutically acceptable surfactants, and one or more pharmaceutically acceptable oils.

A14
cont

78. (Amended) A method of treating a protein kinase related disorder in a patient in need of treatment comprising:

a. diluting a parenteral formulation into a pharmaceutically acceptable solution, said parenteral formulation comprising an ionizable-substituted indolinone of Formula (I);



wherein

R^1 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, hydroxy, alkoxy, C-carboxy, O-carboxy, acetyl, C-amido, C-thioamido, sulfonyl and trihalomethanesulfonyl;

R^2 is selected from the group consisting of hydrogen, halo, alkyl, cycloalkyl, aryl, heteroaryl and heteroalicyclic;

R^3 , R^4 , R^5 and R^6 are independently selected from the group consisting of hydrogen, alkyl, trihaloalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, mercapto, alkylthio, arylthio, sulfinyl, sulfonyl, S-sulfonamido, N-sulfonamido, trihalomethane-sulfonamido, carbonyl, C-carboxy, O-carboxy, C-amido, N-

Sub B3 cont
 amido, cyano, nitro, halo, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, amino and $-NR^{11}R^{12}$;

A15
 R^{11} and R^{12} are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, carbonyl, acetyl, sulfonyl, trifluoromethanesulfonyl and, combined, a five- or six-member heteroalicyclic ring;

R^3 and R^4 , R^4 and R^5 , or R^5 and R^6 may combine to form a six-member aryl ring, a methylenedioxy group or an ethylenedioxy group;


R^7 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, carbonyl, acetyl, C-amido, C-thioamido, amidino, C-carboxy, O-carboxy, sulfonyl and trihalomethane-sulfonyl;

R^9 is $-(alk_1)Z$, wherein Alk_1 is selected from the group consisting of alkyl, alkenyl or alkynyl, and Z is a polar group;

R^8 and R^9 are independently selected from hydrogen and unsubstituted lower alkyl, one or more polyoxyhydrocarbyl compounds, and a buffer;

b. parenterally administering said diluted formulation to said patient.

A16 Sub B3
 80. (Amended) A method of treating a protein kinase related disorder in a patient in need of treatment comprising orally administering to said patient a formulation comprising an ionizable substituted indolinone of Formula (I);



wherein

Sub B4 cont
 R^1 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, hydroxy, alkoxy, C-carboxy, O-carboxy, acetyl, C-amido, C-thioamido, sulfonyl and trihalomethanesulfonyl;

A 16 cont
 R^2 is selected from the group consisting of hydrogen, halo, alkyl, cycloalkyl, aryl, heteroaryl and heteroalicyclic;

R^3 , R^4 , R^5 and R^6 are independently selected from the group consisting of hydrogen, alkyl, trihaloalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, mercapto, alkylthio, arylthio, sulfinyl, sulfonyl, S-sulfonamido, N-sulfonamido, trihalomethane-sulfonamido, carbonyl, C-carboxy, O-carboxy, C-amido, N-amido, cyano, nitro, halo, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, amino and $-NR^{11}R^{12}$;

R^{11} and R^{12} are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, carbonyl, acetyl, sulfonyl, trifluoromethanesulfonyl and, combined, a five- or six-member heteroalicyclic ring;

R^3 and R^4 , R^4 and R^5 , or R^5 and R^6 may combine to form a six-member aryl ring, a methylenedioxy group or an ethylenedioxy group;

R^7 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, carbonyl, acetyl, C-amido, C-thioamido, amidino, C-carboxy, O-carboxy, sulfonyl and trihalomethane-sulfonyl;

R^9 is $-(alk_1)Z$, wherein Alk_1 is selected from the group consisting of alkyl, alkenyl or alkynyl, and Z is a polar group;

R^8 and R^9 are independently selected from hydrogen and unsubstituted lower alkyl, one or more pharmaceutically acceptable surfactants, and one or more pharmaceutically acceptable oils.

Please add the following new claims:

A 17

85. (New) A pharmaceutically acceptable composition comprising a hard gelatin capsule whose filing comprises the formulation of claim 33.

86. (New) A pharmaceutically acceptable composition comprising a soft gelatin capsule whose filing comprises the formulation of claim 33.

87. (New) A pharmaceutically acceptable composition comprising a hard gelatin capsule whose filing comprises the formulation of claim 44.
